Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15778834 | 0.94 | SMN1; SMN2 (0.53) | HDAC4HSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9864404 | 0.83 | HSD11B1 (0.50) | HDAC4HSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5274482 | 0.81 | AKR1C1 (0.56) | HDAC4SMN1; SMN2ALDH1A1LMNANPSR1 | |
| SCHEMBL7895547 | 0.81 | CHRM2 (0.51) | CHRM2CHRM1 | |
| SCHEMBL2321833 | 0.81 | HDAC4 (0.58) | HDAC4HSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1769960 | 0.81 | HDAC4 (0.54) | HDAC4HSD11B1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2550 | 0.81 | HDAC4 (0.54) | HDAC4HSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7767870 | 0.81 | OPRM1 (0.54) | HDAC4HSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3443916 | 0.79 | HDAC4 (0.56) | HDAC4HSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1770373 | 0.79 | HDAC4 (0.56) | HDAC4HSD11B1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| CN-101952275-B | Modulators for amyloid protein beta | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101952275-A | Modulators for amyloid beta | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | HDAC4 3842/4885HSD11B1 396/4885SMN1; SMN2 1705/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | HDAC4 3983/4885HSD11B1 392/4885SMN1; SMN2 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.